EUVIMEDEUVIMED entdecken
Crossref

Antimicrobial peptide chensinin‐1b attenuates T2DM progression in atherosclerotic ApoE −/− mice

Zhongpeng Qiu, Fan Fan, Zhenjia Li, Yue Sun, Dejing Shang iD

Diabetic Medicine · 2026

DOI: 10.1111/dme.70232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Zhongpeng Qiu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science, Liaoning Normal University, Dalian, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Atherosclerosis, Antimicrobial Peptides, Antimicrobial Cationic Peptides. Die Arbeit nennt 36 Literaturangaben. Gefördert von: the Young Science and Technology Star Program from Dalian Municipal Science and Technology Bureau, the Central Government-guided Local Scientific and Technological Development Fund from Dalian Municipal Science and Technology Bureau, Liaoning Normal University Scientific Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Epidemiological evidence suggests that atherosclerosis (AS) may precede or coexist with type 2 diabetes mellitus (T2DM); however, whether anti‐atherosclerotic interventions can reduce T2DM risk remains unclear. Chensinin‐1b (C‐1b), an antimicrobial peptide derived from the skin secretions of Rana chensinensis , has previously demonstrated anti‐atherosclerotic activity, suggesting a potential therapeutic effect against T2DM in the context of AS.

Methods

In an apolipoprotein E‐knockout ( ApoE −/− ) mice model induced by high−fat diet (HFD), the developed process of pathological changes and inflammatory levels of pancreas and aorta were detected at early, middle and late stage of AS, meanwhile the anti−atherosclerotic and anti−diabetic effects of chensinin−1b were investigated.

Results

In the early and middle stages of AS (6−10 weeks), mice fasting blood glucose (FBG) did not change, but atherosclerotic symptoms were significantly exhibited, such as the increased pro−inflammatory factors levels, aortic plaque and blood lipid levels. During the late stage of AS (14 weeks), it was found that the FBG of ApoE −/− mice increased significantly, the pancreas was damaged, the insulin and blood lipid levels were unbalanced, and T2DM symptoms appeared. Treatment with chensinin−1b alleviated the progression of both AS and T2DM, particularly when it was administered in the early stage of the disease.

Conclusions

In ApoE −/− mice, prolonged atherosclerotic pathology is associated with T2DM development. The antimicrobial peptide chensinin−1b attenuates AS and improves metabolic parameters, indicating potential multitarget intervention capabilities. These findings identify chensinin−1b as a candidate molecule for preventing AS−related metabolic abnormalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2AtherosclerosisAntimicrobial PeptidesAntimicrobial Cationic PeptidesAnimalsMiceDisease ProgressionMaleDiet, High-FatMice, KnockoutApolipoproteins EBlood GlucoseDisease Models, AnimalMice, Knockout, ApoEPlaque, Atherosclerotic

Stichwörter der Autor:innen

antimicrobial peptidesatherosclerosisinflammationinsulintype 2 diabetes mellitus

Substanzen

Antimicrobial PeptidesApolipoproteins EBlood GlucoseAntimicrobial Cationic Peptides

Autor:innen und Institutionen

  • School of Life Science, Liaoning Normal University, Dalian, China.
  • Liaoning Provincial Key Laboratory of Biotechnology and Drug Discovery, Liaoning Normal University, Dalian, China.

ORCID-Profile: Dejing Shang

Förderung

  • the Young Science and Technology Star Program from Dalian Municipal Science and Technology Bureau
  • the Central Government-guided Local Scientific and Technological Development Fund from Dalian Municipal Science and Technology Bureau
  • Liaoning Normal University Scientific Research Project
  • National Natural Science Foundation of China

Zitieren

APA

Qiu, Z., Fan, F., Li, Z., Sun, Y., & Shang, D. (2026). Antimicrobial peptide chensinin‐1b attenuates T2DM progression in atherosclerotic ApoE −/− mice. Diabetic Medicine. https://doi.org/10.1111/dme.70232

Vancouver

Qiu Z, Fan F, Li Z, Sun Y, Shang D. Antimicrobial peptide chensinin‐1b attenuates T2DM progression in atherosclerotic ApoE −/− mice. Diabetic Medicine. 2026. doi:10.1111/dme.70232

BibTeX
@article{Qiu2026,
  author = {Qiu, Zhongpeng and Fan, Fan and Li, Zhenjia and Sun, Yue and Shang, Dejing},
  title = {Antimicrobial peptide chensinin‐1b attenuates T2DM progression in atherosclerotic ApoE −/− mice},
  journal = {Diabetic Medicine},
  year = {2026},
  doi = {10.1111/dme.70232}
}
Kostenlos starten →